Want to see MLTX full AI Analyst Report?
MoonLake Immunotherapeutics (MLTX) Stock Statistics & Valuation Metrics
Total Valuation
MoonLake Immunotherapeutics has a market cap or net worth of $976.17M. The enterprise value is $1.00B.
- Market Cap
- $976.17M
- Enterprise Value
- $1.00B
Share Statistics
MoonLake Immunotherapeutics has 85,106,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 85,106,680
- Owned by Insiders
- 26.65%
- Owned by Institutions
- 7.45%
Financial Efficiency
MoonLake Immunotherapeutics’s return on equity (ROE) is -0.75 and return on invested capital (ROIC) is -64.40%.
- Return on Equity (ROE)
- -0.75
- Return on Assets (ROA)
- -0.54
- Return on Invested Capital (ROIC)
- -64.40%
- Return on Capital Employed (ROCE)
- -0.65
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.75M
- Employee Count
- 130
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of MoonLake Immunotherapeutics is -3.14. MoonLake Immunotherapeutics’s PEG ratio is 0.28.
- PE Ratio
- -3.14
- PS Ratio
- 0.00
- PB Ratio
- 2.59
- Price to FCF
- -4.03
- Price to Operating Cash Flow
- -4.04
- PEG Ratio
- 0.28
Income Statement
In the last 12 months, MoonLake Immunotherapeutics had revenue of 0 and earned -227.32M in profits. Earnings per share was -3.53.
- Revenue
- 0
- Gross Profit
- -2.62M
- Operating Income
- -244.83M
- Pretax Income
- -229.71M
- Net Income
- -227.32M
- EBITDA
- -219.85M
- Earnings Per Share (EPS)
- -3.53
Cash Flow
In the last 12 months, operating cash flow was -244.04M and capital expenditures 0, giving a free cash flow of -244.04M billion.
- Operating Cash Flow
- -244.04M
- Free Cash Flow
- -244.04M
- Free Cash Flow per Share
- -2.86
Dividends & Yields
MoonLake Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -24.90%
- Earnings Yield
- -27.82%
Stock Price Statistics
- Beta
- 0.67
- 52-Week Price Change
- 14.12%
- 50-Day Moving Average
- 12.43
- 200-Day Moving Average
- 16.45
- Relative Strength Index (RSI)
- 49.97
- Average Volume (3m)
- 1.69M
Important Dates
MoonLake Immunotherapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
MoonLake Immunotherapeutics as a current ratio of 9.27, with Debt / Equity ratio of 24.86%
- Current Ratio
- 9.27
- Quick Ratio
- 9.27
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 1.18
- Interest Coverage Ratio
- -33.78
Taxes
In the past 12 months, MoonLake Immunotherapeutics has paid 611.00K in taxes.
- Income Tax
- 611.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
MoonLake Immunotherapeutics EV to EBITDA ratio is -2.70, with an EV/FCF ratio of -2.88.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.70
- EV to Free Cash Flow
- -2.88
- EV to Operating Cash Flow
- -2.88
Balance Sheet
MoonLake Immunotherapeutics has $498.46M in cash and marketable securities with $101.62M in debt, giving a net cash position of $396.85M billion.
- Cash & Marketable Securities
- $498.46M
- Total Debt
- $101.62M
- Net Cash
- $396.85M
- Net Cash Per Share
- $4.66
- Tangible Book Value Per Share
- $4.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for MoonLake Immunotherapeutics is $33.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $33.00
- Price Target Upside
- 185.47% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -37.48%
Scores
- Smart Score
- 7
- AI Score
- 52
